City Therapeutics, Clinical-Stage RNAi Therapeutics Developer, Files for Nasdaq Global Market IPO
City Therapeutics filed for a Nasdaq IPO under the ticker CTY, offering 11.1M shares at $18 each for $200M gross proceeds. The biotech company focuses on RNAi therapeutics, with a pipeline including CITY-FXI, CITY-RBP4, and CITY-TFR2. It reported $13.6M revenue and a $58.5M net loss in FY 2025. Proceeds will fund R&D and working capital.
How this was made
The 30-second read
Why it matters
The final prospectus provides concrete capital raise size, offering structure (including over-allotment), and allocation across CITY-FXI, CITY-RBP4, and CITY-TFR2, which informs dilution and runway expectations for traders.
Market read
Traders can use the disclosed IPO size, price, and use of proceeds to frame pre-pricing positioning and post-listing dilution versus funding runway.
What to watch
Demand for IPOs can hinge on broader IPO market conditions and biotech risk appetite, which can overwhelm company-specific fundamentals at pricing.
Background
City Therapeutics is a clinical-stage RNAi biotech developing GalNAc-conjugated siRNA candidates, with collaborations supporting extrahepatic delivery programs.
Ticker impact
City Therapeutics filed a final Nasdaq prospectus for an IPO, offering 11,111,111 shares at $18.00 to raise about $200M gross.
Shares may see initial volatility around pricing and first trading as investors balance funding runway versus dilution and early-stage clinical risk.
The article is a first-report IPO filing with explicit share count, price, and planned spend across three programs, which directly frames dilution and runway.
Market effects
Adds another RNAi clinical-stage issuer to the public market, reinforcing investor appetite for GalNAc delivery and extrahepatic targeting themes.
Primarily US-focused capital markets impact via Nasdaq listing and underwriting syndicate.
Limited direct global read-through beyond biotech funding sentiment and interest in extrahepatic RNAi programs.
Counterpoint
The disclosed pipeline is still early (Phase 1 and planned studies), so the IPO may be more about financing burn than de-risking clinical outcomes.
Key entities
- issuerCity Therapeutics, Inc.
Clinical-stage RNAi therapeutics developer filing for a Nasdaq Global Market IPO under ticker CTY.
- underwriterGoldman Sachs
Lead underwriter listed in the prospectus filing.
- underwriterJefferies
Underwriter listed in the prospectus filing.
- underwriterStifel
Underwriter listed in the prospectus filing.
- underwriterOppenheimer
Underwriter listed in the prospectus filing.
